Mitochondria-Targeted Self-Assembly of Peptide-Based Nanomaterials

Frontiers in Bioengineering and Biotechnology

Yujuan Gao¹  Zhen Luo¹  Yu Yi²  Hao Wang²  Zhongyu Duan³ 

[1] CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing, China;Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, China;School of Chemical Engineering and Technology, Hebei University of Technology, Tianjin, China;

关键词: mitochondrion;    self-assembly;    peptide;    enzyme;    nanomaterials;    cancer therapy;   

DOI  :  10.3389/fbioe.2021.782234

来源: DOAJ

【 摘 要 】

Mitochondria are well known to serve as the powerhouse for cells and also the initiator for some vital signaling pathways. A variety of diseases are discovered to be associated with the abnormalities of mitochondria, including cancers. Thus, targeting mitochondria and their metabolisms are recognized to be promising for cancer therapy. In recent years, great efforts have been devoted to developing mitochondria-targeted pharmaceuticals, including small molecular drugs, peptides, proteins, and genes, with several molecular drugs and peptides enrolled in clinical trials. Along with the advances of nanotechnology, self-assembled peptide-nanomaterials that integrate the biomarker-targeting, stimuli-response, self-assembly, and therapeutic effect, have been attracted increasing interest in the fields of biotechnology and nanomedicine. Particularly, in situ mitochondria-targeted self-assembling peptides that can assemble on the surface or inside mitochondria have opened another dimension for the mitochondria-targeted cancer therapy. Here, we highlight the recent progress of mitochondria-targeted peptide-nanomaterials, especially those in situ self-assembly systems in mitochondria, and their applications in cancer treatments.

【 授权许可】

Unknown